Discovery of potential WEE1 inhibitors via hybrid virtual screening.

Front Pharmacol

Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Department of Clinical Pharmacology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Published: December 2023

G/M cell cycle checkpoint protein WEE1 kinase is a promising target for inhibiting tumor growth. Although various WEE1 inhibitors have entered clinical investigations, their therapeutic efficacy and safety profile remain unsatisfactory. In this study, we employed a comprehensive virtual screening workflow, which included Schrödinger-Glide molecular docking at different precision levels, as well as the utilization of tools such as MM/GBSA and Deepdock to predict the binding affinity between targets and ligands, in order to identify potential WEE1 inhibitors. Out of ten molecules screened, 50% of these molecules exhibited strong inhibitory activity against WEE1. Among them, compounds 4 and 5 showed excellent inhibitory activity with IC values of 1.069 and 3.77 nM respectively, which was comparable to AZD1775. Further investigations revealed that compound 4 displayed significant anti-proliferative effects in A549, PC9, and HuH-7 cells and could also induce apoptosis and G1 phase arrest in PC9 cells. Additionally, molecular dynamics simulations unveiled the binding details of compound 4 with WEE1, notably the crucial hydrogen bond interactions formed with Cys379. In summary, this comprehensive virtual screening workflow, combined with testing and computational modeling, holds significant importance in the development of promising WEE1 inhibitors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10740156PMC
http://dx.doi.org/10.3389/fphar.2023.1298245DOI Listing

Publication Analysis

Top Keywords

wee1 inhibitors
16
virtual screening
12
potential wee1
8
comprehensive virtual
8
screening workflow
8
inhibitory activity
8
wee1
7
discovery potential
4
inhibitors
4
inhibitors hybrid
4

Similar Publications

WEE1 Confers Resistance to KRAS Inhibitors in Non-Small Cell Lung Cancer.

Cancer Lett

December 2024

Division of Collaborative Research and Developments, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan; Division of Translational Genomics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan. Electronic address:

KRAS inhibitors sotorasib and adagrasib have been approved for the treatment of KRAS-mutant non-small cell lung cancer (NSCLC). However, the efficacy of single-agent treatments is limited, presumably due to multiple resistance mechanisms. To overcome these therapeutic limitations, combination strategies that potentiate the antitumor efficacy of KRAS inhibitors must be developed.

View Article and Find Full Text PDF

Background: Glioblastoma, a lethal high-grade glioma, has not seen improvements in clinical outcomes in nearly 30 years. Ion channels are increasingly associated with tumorigenesis, and there are hundreds of brain-penetrant drugs that inhibit ion channels, representing an untapped therapeutic resource. The aim of this exploratory drug study was to screen an ion channel drug library against patient-derived glioblastoma cells to identify new treatments for brain cancer.

View Article and Find Full Text PDF

BX517, an inhibitor of the mammalian phospholipid-dependent kinase 1 (PDK1), antagonizes sucrose-induced plant growth and represses the target of rapamycin (TOR) signaling and the cell cycle through WEE1 kinase in Arabidopsis thaliana.

J Plant Physiol

November 2024

Instituto de Investigaciones Químico Biológicas, Laboratorio de Biotecnología Molecular de Plantas, Universidad Michoacana de San Nicolás de Hidalgo, Ed U3, Ciudad Universitaria, Morelia, Michoacán, Mexico, CP 58030. Electronic address:

The target of rapamycin (TOR) signaling pathway is critical for plant growth and stress adaptation through maintaining the proper balance between cell proliferation and differentiation. Here, by using BX517, an inhibitor of the mammalian phosphoinositide-dependent protein kinase 1 (PDK1), we tested the hypothesis that a plant ortholog of PDK1 could influence the TOR complex activity and its target, the S6 ribosomal protein kinase (S6K) in Arabidopsis seedlings. Through locally applying sucrose to leaves, which promotes root growth and plant biomass production via TOR signaling, we could demonstrate the opposite trend upon BX517 treatment, which antagonized sucrose-induced plant growth and overly decreased root development through inhibiting the expression of mitotic cyclins CYCB1 and CYCA3 in root meristems.

View Article and Find Full Text PDF

Synergistic effects of MK-1775 and gemcitabine on cytotoxicity in non-small cell lung cancer.

Heliyon

November 2024

Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. Chemotherapy is crucial in NSCLC treatment, and targeting Wee1 kinase, a key regulator of the G2/M cell cycle checkpoint, may enhance the efficacy of cytotoxic agents. This study investigates the potential of the Wee1 inhibitor MK-1775 in combination with gemcitabine and pemetrexed to enhance cytotoxicity in NSCLC cell lines.

View Article and Find Full Text PDF

Background: Adavosertib (AZD1775) is a small-molecule Wee1 inhibitor. Durvalumab is a PD-L1 inhibitor.

Objective: The safety, tolerability, pharmacokinetics, and preliminary antitumor activity of adavosertib plus durvalumab were evaluated in patients with refractory solid tumors to define the maximum tolerated dose (MTD) and recommended phase II dose (RP2D).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!